Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (63)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 5

  3. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

    Antimicrobial agents and chemotherapy, Vol. 68, Núm. 11, pp. e0092424

  4. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 2, pp. 223-230

  5. Corrigendum to “Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions” [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150] (International Journal of Antimicrobial Agents (2024) 63(5), (S0924857924000682), (10.1016/j.ijantimicag.2024.107150))

    International Journal of Antimicrobial Agents

  6. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 279-296

  7. Deep Intraclonal Analysis for the Development of Vaccines against Drug-Resistant Klebsiella pneumoniae Lineages

    International Journal of Molecular Sciences, Vol. 25, Núm. 18

  8. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  9. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

    Infection

  10. Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study

    Eurosurveillance, Vol. 29, Núm. 15

  11. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 10, pp. 2591-2597

  12. Impact of transferable β-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 79, Núm. 11, pp. 3023-3028

  13. In vitro activity of cefiderocolagainst European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations

    Microbiology Spectrum, Vol. 12, Núm. 8

  14. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  15. Mitomycin C as an Anti-Persister Strategy against Klebsiella pneumoniae: Toxicity and Synergy Studies

    Antibiotics, Vol. 13, Núm. 9

  16. Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis

    European Journal of Haematology

  17. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group

    Clinical Microbiology and Infection

  18. Rapid and Simple Morphological Assay for Determination of Susceptibility/Resistance to Combined Ciprofloxacin and Ampicillin, Independently, in Escherichia coli

    Antibiotics, Vol. 13, Núm. 7

  19. Regulation of anti-phage defense mechanisms by using cinnamaldehyde as a quorum sensing inhibitor

    Frontiers in Microbiology, Vol. 15

  20. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 9, pp. 2132-2141